UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 2, 2006
BIOPHAN TECHNOLOGIES, INC.
--------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-26057 82-0507874
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
150 Lucius Gordon Drive, Suite 215
West Henrietta, New York 14586
--------------------------------------- ---------
(Address of principal executive offices) (Zip code)
(585) 214-2441
-------------------------
(Registrant's telephone number)
Item 7.01 Regulation FD Disclosure
On May 2, 2006, we issued a press release entitled " Biophan Technologies
Announces Research and Development Partnership with FDA to Study MRI Safety" The
press release is filed herewith as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Number Exhibit
99.1 Press Release dated May 2, 2006: "Biophan Technologies Announces
Research and Development Partnership with FDA to Study MRI Safety"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
----------------------------
(Registrant)
/S/ Darryl L. Canfield
Date 5/2/06 ----------------------------
(Signature) (Signature)
Darryl L. Canfield
CFO, Treasurer, Secretary
Principal Financial Officer)